GCT’s Historic Potential | Priorities and Trade Offs
Monday, May 2, 2022
This panel features industry leaders who will discuss what the future may hold for gene and cell therapy. Which applications are likely to have the greatest impact? What are the key hurdles to be overcome? What specific platforms and technologies may enable optimal solutions? In what disease areas? Learn more about these and other questions as the panelists discuss the future potential of GCT.
- Moderator:
-
- Jean-François Formela, MD
-
- Partner, Atlas Venture
- Panelists:
-
- Pablo Cagnoni, MD
-
- CEO, Rubius Therapeutics
- Kristen Hege, MD
-
- Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb
- Andrew Plump, MD, PhD
-
- President, R&D, Takeda
- Catherine Stehman-Breen, MD
-
- CEO, Chroma Medicine